The FDA has expanded the approval of ipilimumab (Yervoy) to include the treatment of pediatric melanoma patients 12 years and older with unresectable or metastatic disease. (Source: CancerNetwork)
from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2uwt3jM
via IFTTT
Εγγραφή σε:
Σχόλια ανάρτησης (Atom)
Δημοφιλείς αναρτήσεις
-
Objective Outpatient parenteral antimicrobial therapy (OPAT) provides opportunities for improved cost savings, but in the UK, implementation...
-
Abstract Purpose Overcoming the flaws of current data management conditions in head and neck oncology could enable integrated informatio...
-
http://orl-agios.blogspot.com/2017/06/the-preclinical-anticancer-effect-of.html Flavonoids present in foods were considered non-absorbable b...
-
Vol.31 No.5 from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/1k8FKtW via IFTTT
-
Publication date: Available online 24 December 2017 Source: European Journal of Radiology Author(s): Wenbin Jiang, Hongwei Xue, Qinqin W...
-
Geographic region: Does it matter in cutaneous melanoma of the head and neck? Laryngoscope. 2017 Jun 05;: Authors: Kılıç S, Unsal AA,...
-
We report an unusual case of a strangulated internal hernia resulting from a right paraduodenal fossa hernia (PDH) in the context of bowel m...
-
Objective. We compared the effects of transcranial direct current stimulation at different cortical sites (premotor and motor primary cortex...
-
December from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/1luSNqR via IFTTT
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου